Buerger's disease often involves repeated acute episodes of ischaemia over several years. The disease intensifies at 30 to 40 years of age and then regresses. It is rarely present in patients >60 years of age.[62]Szuba A, Cooke JP. Thromboangiitis obliterans: an update on Buerger's disease. West J Med. 1998 Apr;168(4):255-60.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1304949/pdf/westjmed00331-0029.pdf
http://www.ncbi.nlm.nih.gov/pubmed/9584663?tool=bestpractice.com
Smoking cessation
Patients who continue to smoke have a 19% major amputation rate; this is 2.73 times greater than for people who have ceased smoking, according to one study.[32]Ohta T, Ishioashi H, Hosaka M, et al. Clinical and social consequences of Buerger disease. J Vasc Surg. 2004 Jan;39(1):176-80.
http://www.ncbi.nlm.nih.gov/pubmed/14718836?tool=bestpractice.com
[34]Sasaki S, Sakuma M, Yasuda K. Current status of thromboangiitis obliterans (Buerger's disease) in Japan. Int J Cardiol. 2000 Aug 31;75(suppl 1):S175-81.
http://www.ncbi.nlm.nih.gov/pubmed/10980360?tool=bestpractice.com
Smoking increases flare-ups and reduces ulcer healing. A return to smoking following cessation may lead to a flare-up of the disease. Smoking only 1 or 2 cigarettes a day, using smokeless tobacco (chewing tobacco), or using nicotine replacement therapy may all keep the disease active.[19]Lie JT. Thromboangiitis obliterans (Buerger's disease) and smokeless tobacco. Arthritis Rheum. 1988 Jun;31(6):812-3.
http://www.ncbi.nlm.nih.gov/pubmed/3382454?tool=bestpractice.com
[20]Joyce JW. Buerger's disease (thromboangiitis obliterans). Rheum Dis Clin North Am. 1990 May;16(2):463-70.
http://www.ncbi.nlm.nih.gov/pubmed/2189162?tool=bestpractice.com
Smoking is best stopped through smoking cessation classes, although varenicline has been shown to be beneficial. Varenicline is a selective nicotinic receptor partial agonist that is used as an aid for smoking cessation.
Amputations
In one study, 34% of patients had an amputation within 15 years of diagnosis.[2]Le Joncour A, Soudet S, Dupont A, et al. Long-term outcome and prognostic factors of complications in thromboangiitis obliterans (Buerger's disease): a multicenter study of 224 patients. J Am Heart Assoc. 2018 Dec 4;7(23):e010677.
https://www.doi.org/10.1161/JAHA.118.010677
http://www.ncbi.nlm.nih.gov/pubmed/30571594?tool=bestpractice.com
The amputation-free survival rates at 5 and 10 years were 85% and 74%, respectively. Limb infection was associated with an increased amputation rate.[2]Le Joncour A, Soudet S, Dupont A, et al. Long-term outcome and prognostic factors of complications in thromboangiitis obliterans (Buerger's disease): a multicenter study of 224 patients. J Am Heart Assoc. 2018 Dec 4;7(23):e010677.
https://www.doi.org/10.1161/JAHA.118.010677
http://www.ncbi.nlm.nih.gov/pubmed/30571594?tool=bestpractice.com
Repeated amputations are often needed and are an indication of the disease severity.
Life expectancy
Life expectancy is not altered in patients with Buerger's disease: 90% to 95% survive for 10 years; 85% survive for 25 years.[1]Mills JL, Porter JM. Buerger's disease (thromboangiitis obliterans). Ann Vasc Surg. 1991 Nov;5(6):570-2.
http://www.ncbi.nlm.nih.gov/pubmed/1772769?tool=bestpractice.com
[32]Ohta T, Ishioashi H, Hosaka M, et al. Clinical and social consequences of Buerger disease. J Vasc Surg. 2004 Jan;39(1):176-80.
http://www.ncbi.nlm.nih.gov/pubmed/14718836?tool=bestpractice.com
[63]Ates A, Yekeler I, Ceviz M, et al. One of the most frequent vascular diseases in northeastern of Turkey: thromboangiitis obliterans or Buerger's disease (experience with 344 cases). Int J Cardiol. 2006 Jul 28;111(1):147-53.
http://www.ncbi.nlm.nih.gov/pubmed/16580754?tool=bestpractice.com
This is probably because Buerger's disease is not associated with cardiovascular risk factors, aside from smoking.